FOXO4-DRI 10mg

FOXO4-DRI is a synthetic peptide that has garnered attention in preclinical research due to its capacity to selectively target senescent cells. These cells, often referred to as "zombie cells," accumulate with age and contribute to various age-related dysfunctions by secreting pro-inflammatory factors.

Researchers are exploring FOXO4-DRI's potential in mitigating the effects associated with senescent cell accumulation. The peptide's mechanism involves disrupting the interaction between FOXO4 and p53, which is critical for the survival of senescent cells.

Mechanism of Action

FOXO4-DRI operates by specifically interfering with the FOXO4/p53 protein-protein interaction within senescent cells. In normal cells, FOXO4 forms a complex with p53, a tumor suppressor protein, which is vital for cellular health and protection against DNA damage. However, in senescent cells, this interaction is exploited to prevent their apoptotic clearance. By disrupting this binding, FOXO4-DRI promotes the apoptosis of senescent cells, thereby reducing their harmful accumulation and associated secretome.

Structure and Class

FOXO4-DRI is a synthetic peptide, typically comprising approximately 12 amino acids. It was designed to mimic a specific region of the FOXO4 protein that is involved in its binding to p53. This targeted molecular design classifies it as a peptidomimetic, allowing it to modulate specific intracellular protein interactions.

Primary Research Areas

The primary research area for FOXO4-DRI centers on its senolytic properties. Researchers are investigating its potential applications in conditions associated with aging and senescent cell accumulation, including metabolic disorders, tissue repair, and overall longevity. Studies primarily focus on its ability to clear senescent cells and observe the downstream effects on tissue function and systemic health.

Notable Peer-Reviewed Findings

Early investigational studies in research models have shown that FOXO4-DRI administration can lead to the selective elimination of senescent cells. This clearance has been associated with improvements in various age-related markers and functions, including aspects of physical activity, coat density, and kidney function in preclinical studies. These findings suggest that targeting FOXO4/p53 interaction could be a viable strategy for addressing certain age-related processes at the cellular level.